Sympatholytic (Adrenergic Blocking) Agents

DrugDrug NameDrug Indication
DB00320DihydroergotamineFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
DB00692PhentolamineUsed as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.
DB00696ErgotamineFor use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
DB01049Ergoloid mesylateIt was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.[A32926] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[L2637] To know more about the individual components of the ergoloid mixture, please visit [DB13345] and [DB11274]
DrugDrug NameTargetType
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Dtarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Btarget
DB00320DihydroergotamineCytochrome P450 3A4enzyme
DB00320DihydroergotamineAlpha-2A adrenergic receptortarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 2Btarget
DB00320DihydroergotamineP-glycoprotein 1transporter
DB00692PhentolamineAlpha-2A adrenergic receptortarget
DB00692PhentolamineAlpha-1A adrenergic receptortarget
DB00692PhentolamineAlpha-1B adrenergic receptortarget
DB00692PhentolamineAlpha-1D adrenergic receptortarget
DB00696ErgotamineAlpha-1A adrenergic receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Dtarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Btarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Atarget
DB00696ErgotamineAlpha-2A adrenergic receptortarget
DB00696ErgotamineDopamine D2 receptortarget
DB00696ErgotamineAlpha-2B adrenergic receptortarget
DB00696ErgotamineSodium-dependent noradrenaline transportertarget
DB00696ErgotamineCytochrome P450 3A4enzyme
DB00696ErgotamineAlpha-1B adrenergic receptortarget
DB00696ErgotamineAlpha-1D adrenergic receptortarget
DB00696ErgotamineP-glycoprotein 1transporter
DB00696ErgotamineD(1) dopamine receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Atarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Ftarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Ctarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Btarget
DB01049Ergoloid mesylateDopamine receptortarget
DB01049Ergoloid mesylateAlpha adrenergic receptortarget
DB01049Ergoloid mesylateBeta adrenergic receptortarget
DB01049Ergoloid mesylateSerotonin Receptorstarget
DB01049Ergoloid mesylateCytochrome P450 3A4enzyme